Consonance-Hfw Acquisition Corp. Reports Earnings Results for the Second Quarter Ended June 30, 2021
August 09, 2021 at 06:09 am EDT
Share
Consonance-HFW Acquisition Corp. announced earnings results for the second quarter ended June 30, 2021. For the second quarter, the company announced operating loss was USD 1.049 million. Net loss was USD 3.584 million. For the half year, operating loss was USD 2.114 million. Net loss was USD 3.817 million.
Surrozen, Inc. is a clinical-stage biotechnology company. The Company is engaged in discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a range of organs and tissues. The Company's lead product candidates are multi-specific, antibody-based therapeutics that mimic the roles of naturally occurring Wnt or R-spondin proteins, which are involved in activation and enhancement of the Wnt pathway. Its two technologies, Surrozen Wnt signal Activating Protein (SWAP) and Surrozen Wnt signal Enhancers Engineered for Tissue Specificity (SWEETS), enable it to potently and selectively modulate Wnt signaling through the generation of Wnt and R-spondin mimetics. SWAP molecules are designed to mimic the activity of naturally occurring Wnt proteins. SWEETS molecules are designed to amplify the body's response to naturally occurring Wnt proteins. Its product candidates include SZN-1326, SZN-043 and SZN-413.
SURROZEN, INC. 
